Public trial registry of the CCC-Munich

Trial ZEAL-1L 213400

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
ZEAL-1L 213400
World
Full title
:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Asklepios Klinik Gauting, Telefon:
Indications
Classification Code Description
ICD-10-GM C34.- Bösartige Neubildung der Bronchien und der Lunge
- lung cancers
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Double blinded
World
Phase
:
III
Status
World
Status
:
Recruitment active
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2024-10-31 / Unknown
Participants
Function Prename Surname Organization
World Principal Investigator NIELS REINMUTH Keine Organisationseinheit angegeben Magnifier